Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes

Benzinga · 4d ago

Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the publication by Yale researchers of new preclinical research on simufilam in the peer-reviewed journal Cells1. The study examined simufilam’s effects in a human cell line engineered to knock out the TSC2 gene to model cellular changes associated with TSC. The work was conducted by researchers at Yale School of Medicine, including Angélique Bordey, PhD, who also serves as Senior Vice President (SVP), Neuroscience at Filana Therapeutics.